Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin

David J. M. Lewis, Zhiming Huo, Susan Barnett et al. · 2009

Read Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin by David J. M. Lewis, Zhiming Huo, Susan Barnett et al. (2009) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/plos-pone-0006999.txt.

Introduction

David Lewis, Zhiming Huo, Susan Barnett, and colleagues reported a vaccine safety finding in PLOS ONE in 2009. An earlier nasal flu vaccine had been linked to Bell's palsy, a temporary facial nerve paralysis. That vaccine carried an active bacterial toxin as an adjuvant. Which component caused the problem was unresolved.

The team gave a genetically detoxified mutant of the E. coli heat labile toxin through the nose. Facial nerve paralysis still followed in their tests. The result points at the toxin component itself, even in weakened form. It is a caution for any vaccine delivered through the nasal route.

Catalog record

CREATORDavid J. M. Lewis, Zhiming Huo, Susan Barnett et al.
YEAR2009
COLLECTIONPAPERS
FORMATTXT
FILE SIZE25 KB
LICENSECreative Commons Attribution License
RIGHTSCC BY
SOURCEPLOS ONE

Source: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0006999

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Transient Facial Nerve Paralysis (Bell's Palsy) following Intranasal Delivery of a Genetically Detoxified Mutant of Escherichia coli Heat Labile Toxin Authors: David J. M. Lewis, Zhiming Huo, Susan Barnett, Ingrid Kromann, Rafaela Giemza, Eva Galiza, Maria Woodrow, Birgit Thierry-Carstensen, Peter Andersen, Deborah Novicki, Giuseppe Del Giudice, Rino Rappuoli Published: 2009, PLOS ONE DOI: 10.1371/journal.pone.0006999 ABSTRACT An association was previously established between facial nerve paralysis (Bell's palsy) and intranasal administration of an inactivated influenza virosome vaccine containing an enzymatically active Escherichia coli Heat Labile Toxin (LT) adjuvant. The individual component(s) responsible for paralysis were not identified, and the vaccine was withdrawn. Subjects participating in two contemporaneous non-randomized Phase 1 clinical trials of nasal subunit vaccines against Human Immunodeficiency Virus and tuberculosis, both of which employed an enzymatically inactive non-toxic mutant LT adjuvant (LTK63), underwent active follow-up for adverse events using diary-cards and clinical examination. Two healthy subjects experienced transient peripheral facial nerve palsies 44 and 60 days after passive nasal instillation of LTK63, possibly a result of retrograde axonal transport after neuronal ganglioside binding or an inflammatory immune response, but without exaggerated immune responses to LTK63. While the unique anatomical predisposition of the facial nerve to compression suggests nasal delivery of neuronal-binding LT–derived adjuvants is inadvisable, their continued investigation as topical or mucosal adjuvants and antigens appears warranted on the basis of longstanding safety via oral, percutaneous, and other mucosal routes. INTRODUCTION Mucosal immunization via intranasal route has received much attention in recent years [1] due to potential advantages of needle-free delivery and enhanced mucosal immune responses against infections such as influenza or Human Immunodeficiency Virus (HIV), which can be enhanced by co-administration of effective mucosal adjuvants such as mutants of Escherichia coli heat labile toxin (LT) [2] . However, this immunization approach raised concerns after a strong epidemiological association was reported [3] between facial nerve paralysis (Bell's Palsy) and intranasal administration of inactivated influenza virosome vaccine “NasalFlu” containing an enzymatically active mutant LT adjuvant [4] . Retrospective analysis did not identify relative contributions of vaccine components [3] , and NasalFlu was withdrawn. We report two cases of transient Bell's Palsy following nasal administration of a genetically detoxified LT adjuvant (LTK63) [2] during two Phase 1 vaccine trials. METHODS The cases reported here occurred during two contemporaneous, open-label, Phase 1 clinical vaccine trials of safety and immunogenicity at the same clinical site (St George's Vaccine Institute, London). No formal sample size calculations were made, as is usual in this early stage of evaluation. Full details of trials outcomes are in preparation for publication. Briefly, nine BCG vaccine-naive healthy subjects aged 18–45 were entered into a non-randomized Phase 1 trial of a nasal Mycobacterium tuberculosis subunit vaccine [5] (full protocol available on ClinicalTrials.gov NCT00440544: http://clinicaltrials.gov/ct2/show/NCT00440544 , EudraCT: 2005-005983-10). The first four subjects received two nasal immunizations (days 0 and 56) with 100 µg Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein alone, and the subsequent five subjects received two nasal immunizations (days 0 and 56) of 100 µg Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein mixed with 30 µg LTK63. After the event reported here the trial was terminated prior to recruitment of subsequent planned groups. In the contemporaneous trial, 30 healthy subjects aged 18–45 were entered into a non-randomized Phase 1 clinical trial of a nasal HIV glycoprotein-140 subunit vaccine [6] (full protocol available on ClinicalTrials.gov NCT00369031: http://clinicaltrials.gov/ct2/show/NCT00369031 , EudraCT: 2005-005140-81), and allocated to one of three consecutively-recruited groups (10 per group) to receive three intranasal immunisations (days 0, 28, and 56) with either: 100 µg HIV glycoprotein-140 mixed with 30 µg LTK63, 100 µg HIV glycoprotein-140 alone, or 30 µg LTK63 alone. All subjects received two intramuscular immunizations with 100 µg HIV glycoprotein-140 mixed with MF59 adjuvant [7] on days 112 and 196. Following the case reported here 4 subjects in the group receiving 30 µg LTK63 alone nasally underwent only one nasal immunization, but did receive two intramuscular immunizations. The subject reported here had no further immunizations after the first nasal immunization with 30 µg LTK63 alone. COLLECTION, PROCESSING, AND ANALYSIS OF SERUM AND NASAL LAVAGE SAMPLES FOR IMMUNE RESPONSES TO LTK63 Blood and nasal samples were obtained at pre-defined time points before and after immunization. Blood was collected by antecubital fossa venepuncture, serum separated and frozen at −20°C. Nasal lavage with 5 mL sterile water was performed via urinary catheter placed the anterior nares bilaterally, and samples frozen at −80°C. IgG and IgA antibodies to LTK63 were detected by indirect ELISA [8] , expressed in µg/mL using a human immunoglobulin standard (NIBSC, UK). INVESTIGATIONS FOR ALTERNATIVE CAUSES OF FACIAL NERVE PARALYSIS Pre- and post-immunization serum or plasma samples were retrospectively analysed for evidence of the most common conditions associated with Bell's palsy including serology/PCR/antigen detection of infection with Human Immunodeficiency Virus, Epstein-Barr Virus (EBV), Varicella zoster virus (VZV), Borrelia burgdorferi , measles, mumps, Herpes simplex 1 and 2 (HSV) and cytomegalovirus (CMV); or autoimmune diseases including antinuclear antibodies (ANA), anti-neutrophil cytoplasmic antibodies (ANCA) and Angiotensin Converting Enzyme (ACE) levels. Both subjects declined radiological examinations. ETHICS All subjects provided written informed consent before undergoing screening or participation in the trials, which were both approved by St George's Research Ethics Committee and UK Medicines and Healthcare products Regulatory Agency. In addition the two subjects reported here provided additional written consent for publication of details which may include identifying information. RESULTS A healthy 29 year old, white male enrolled into nasal Mycobacterium tuberculosis subunit vaccine trial 2005-005983-10. He reported an uncomplicated nasal procedure age 6, insertion of tympanic membrane grommets in childhood, mild conjunctivitis when pollen count high, mild itching after prolonged grass contact, but no seasonal rhinitis, neurological disease, migraine or regular medications. Screening HIV, hepatitis B and C serology, hematology and biochemistry were negative or normal. Mantoux test and ‘QuantiFERON-TB Gold’ (Cellestis, UK) were negative for latent tuberculosis. Medical examination including ear, nose and throat (ENT) and cranial nerves was normal apart from scar on right tympanic membrane. Chest radiograph was normal. He received 100 µg Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein and 30 µg LTK63, in 300 µL physiological buffer, by passive instillation of drops divided equally between right and left anterior nares. A diary was issued to record symptoms. On day 1 he recorded mild malaise, ENT discomfort, and cough. Examination on day 7 was normal. Between days 34–43 he recorded mild itching of eyes and took loratidine. Examination on day 43 was normal. Between days 45–48 he experienced mild coryza and nasal discharge treated with acetaminophen. Examination on day 56 was normal, and he received second nasal immunization with Ag85B-ESAT6 and LTK63 as before. Between days 57–61 took loratidine for a sensation of fluid in right ear. On day 58 he experienced a migraine-like visual aura bilaterally, lasting 20 minutes. On day 60 he noticed mild right sided post-auricular pain, followed by abnormality of taste, worsening over day 61. On day 62 (5 days after second immunization) he developed right-sided facial asymmetry and increased tear production. On examination on day 64 he was afebrile, cardiovascular, respiratory, abdominal examination normal, no mastoid tenderness, rashes or peri-auricular vesicles. ENT normal except clear fluid behind non-inflamed right tympanic membrane. Sense of smell normal on testing. Cranial nerves 2–6 normal, corneal reflex intact, pupils equal and

Read the complete text